This $647,486 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research by Inlighta Biosciences L.L.C., a woman-owned small business, to design and develop calcium-sensing receptor (CaSR) targeted theragnostic agents. The key goals of this Phase I research project are to:
- Optimize and characterize CaSR-binding TNCA analogs as agonists and antagonists for potential drug candidates.
- Perform in vivo mapping of CaSR distribution in a preclinical polycystic kidney disease (PKD) rat model using PET imaging.
The successful completion of these preclinical studies aims to provide critical data for advancing the development of CaSR-specific drugs and companion diagnostic imaging agents for treating various CaSR-associated diseases, including PKD. This award builds upon Inlighta Biosciences' prior federally-funded research on its protein-based MRI contrast agent technology.
Generated 3/4/25, 7:58 AM